BioRegen Labs is a Basel-based biotechnology company that has achieved significant funding success with $150 million raised through Series C, making it one of the most well-capitalized companies in the regenerative medicine sector. The company's name clearly indicates a focus on regenerative biology and therapeutic applications, likely involving stem cell therapies, tissue engineering, gene therapies, or other regenerative medicine approaches.
Based in Basel, Switzerland, BioRegen Labs operates in one of Europe's premier pharmaceutical and biotechnology hubs, home to major pharmaceutical companies like Novartis and Roche. This location provides access to world-class research infrastructure, regulatory expertise, and proximity to key European markets. The substantial Series C funding of $150 million demonstrates strong institutional investor confidence and likely supports advanced clinical development programs, manufacturing capabilities, and potential commercial preparations. Regenerative medicine represents one of the most promising and rapidly growing sectors in biotechnology, with applications spanning multiple therapeutic areas including oncology, autoimmune diseases, and degenerative conditions.
| Date | Round | Amount | Lead Investor |
|---|---|---|---|
| Jan 2026 | Series C+ | $150M | Novo Holdings |
A Basel-based regenerative medicine company with $150M in Series C funding, developing advanced regenerative therapies and technologies.
BioRegen Labs has raised $150M in total funding, with their most recent round being a Series C. The company operates in the Biotech sector.
BioRegen Labs operates in the Biotech sector. A Basel-based regenerative medicine company with $150M in Series C funding, developing advanced regenerative therapies and technologies.
